Evidence map›Paper›PMID 36767006›Full record

ArticleHealthcare (Basel, Switzerland)2023

Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area.

Denis Horgan, Yosr Hamdi, Jonathan A Lal, Teresia Nyawira, Salomé Meyer, Dominique Kondji, Ngiambudulu M Francisco, Roselle De Guzman, Anupriya Paul, Branka Bernard and 15 more

Abstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Observational
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Denis HorganEuropean Alliance for Personalised Medicine, 1040 Brussels, Belgium.
Yosr HamdiLaboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Jonathan A LalDepartment of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, India.
Teresia NyawiraNational Commission for Science, Technology and Innovation in Kenya (NACOSTI), Nairobi 00100, Kenya.
Salomé MeyerCancer Alliance, Cape Town 7700, South Africa.
Dominique KondjiHealth & Development Communication, Building Capacity for Better Health in Africa, Yaounde P.O. Box 2032, Cameroon.
Ngiambudulu M FranciscoGrupo de Investigação Microbiana e Imunológica, Instituto Nacional de Investigação em Saúde (National Institute for Health Research), Luanda 3635, Angola.ORCID 0000-0003-3255-8968
Roselle De GuzmanOncology and Pain Management Section, Manila Central University-Filemon D. Tanchoco Medical Foundation Hospital, Caloocan 1400, Philippines.
Anupriya PaulDepartment of Mathematics and Statistics, Faculty of Science, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, India.
Branka BernardEuropean Alliance for Personalised Medicine, 1040 Brussels, Belgium.
Krishna Reddy NallamallaACCESS Health India, Hyderabad 500086, India.
Woong-Yang ParkSamsung Medical Center, Samsung Genome Institute, Sungkyunkwan University, Seoul 06351, Republic of Korea.
Vijay TriapthiDepartment of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, India.ORCID 0000-0002-6103-0890
Ravikant TripathiDepartment Health Government of India, Ministry of Labor, New Delhi 110001, India.
Amber JohnsCancer Division, Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney 2010, Australia.
Mohan P SinghCenter of Biotechnology, University of Allahabad, Allahabad 211002, India.
Maude E PhippsJeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Subang Jaya 47500, Selangor, Malaysia.ORCID 0000-0001-8314-068X
France DubePrecision Medicine and Breast Cancer Department, Astra Zeneca, 1800 Concord Pike, Wilmington, DE 19803, USA.
Hadi Mohamad Abu RasheedQatar Cancer Society, Doha 22944, Qatar.ORCID 0000-0002-7705-2170
Marta KozaricEuropean Alliance for Personalised Medicine, 1040 Brussels, Belgium.
Joseph A PintoCenter for Basic and Translational Research, Auna Ideas, Lima 15036, Peru.
Stephen Doral StefaniUNIMED RS, Porto Alegre 90040-180, Brazil.
Maria Eugenia Aponte RuedaVenezuelan Breast Cancer Research and Education Foundation, Caracas 1060, Venezuela.
Ricardo Fujita AlarconCentro de Genética y Biología Molecular, Universidad de San Martín de Porres, Lima 15024, Peru.
Hugo A Barrera-SaldanaInnbiogem SC/Vitagenesis SA at National Laboratory for Services of Research, Development, and Innovation for the Pharma and Biotech Industries (LANSEIDI) of CONACyT Vitaxentrum Group, Monterrey 64630, Mexico.

Funding

Erasmus+ Programme of the European Union 2019-1-HR01-KA203-061010.
6 · The paper itself

Abstract

Radical new possibilities of improved treatment of cancer are on offer from an advanced medical technology already demonstrating its significance: next-generation sequencing (NGS). This refined testing provides unprecedentedly precise diagnoses and permits the use of focused and highly personalized treatments. However, across regions globally, many cancer patients will continue to be denied the benefits of NGS as long as some of the yawning gaps in its implementation remain unattended. The challenges at the regional and national levels are linked because putting the solutions into effect is highly dependent on cooperation between regional- and national-level cooperation, which could be hindered by shortfalls in interpretation or understanding. The aim of the paper was to define and explore the necessary conditions for NGS and make recommendations for effective implementation based on extensive exchanges with policy makers and stakeholders. As a result, the European Alliance for Personalised Medicine (EAPM) developed a maturity framework structured around demand-side and supply-side issues to enable interested stakeholders in different countries to self-evaluate according to a common matrix. A questionnaire was designed to identify the current status of NGS implementation, and it was submitted to different experts in different institutions globally. This revealed significant variability in the different aspects of NGS uptake. Within different regions globally, to ensure those conditions are right, this can be improved by linking efforts made at the national level, where patients have needs and where care is delivered, and at the global level, where major policy initiatives in the health field are underway or in preparation, many of which offer direct or indirect pathways for building those conditions. In addition, in a period when consensus is still incomplete and catching up is needed at a political level to ensure rational allocation of resources-even within individual countries-to enable the best ways to make the necessary provisions for NGS, a key recommendation is to examine where closer links between national and regional actions could complement, support, and mutually reinforce efforts to improve the situation for patients.

Indexed as

adoptionavailabilityframeworkmaturity frameworkmolecular tumour boardnext-generation sequencingNGSpolicy makersreimbursementsurvey

Identifiers

PMID36767006
PMCPMC9914369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.